Edition:
United States

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

1.21USD
14 Dec 2018
Change (% chg)

$-0.01 (-0.82%)
Prev Close
$1.22
Open
$1.20
Day's High
$1.22
Day's Low
$1.20
Volume
8,687
Avg. Vol
16,486
52-wk High
$15.75
52-wk Low
$1.12

Latest Key Developments (Source: Significant Developments)

Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios
Thursday, 21 Dec 2017 02:37am EST 

Dec 21 (Reuters) - Summit Therapeutics Plc ::SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA.AGREEMENT GRANTS EUROFARMA LABORATÓRIOS SA RIGHTS IN LATIN AMERICA TO SUMMIT'S PRECISION ANTIBIOTIC RIDINILAZOLE IN DEVELOPMENT FOR THE TREATMENT OF CDI.SUMMIT RETAINS COMMERCIALISATION RIGHTS IN ALL OTHER COUNTRIES.RIDINILAZOLE IS A TARGETED ANTIBIOTIC THAT HAS THE POTENTIAL AS A FRONTLINE THERAPY TO TREAT INITIAL INFECTION AND PRESERVE PATIENTS' MICROBIOMES TO REDUCE THE RATE OF RECURRENT CDI .  Full Article

Photo

Japan Mitsubishi Corp to acquire 25 percent stake in Bangladesh LNG terminal

SINGAPORE Japan's Mitsubishi Corp on Friday said it has agreed to acquire 25 percent of Bangladesh's Summit Liquefied Natural Gas (LNG) terminal and plans to help develop an offshore receiving site in the South Asian country.

No consensus analysis data available.